Oncology News | pharmaphorum

News

Two new cancer Priority Reviews for Roche

Roche has announced that the FDA has granted Priority Review to two of its drugs – personalised lung cancer medicine entrectinib and lymphoma treatment polat

News

Trial could unlock new prostate cancer sales for Pfizer/Aste...

Pfizer and Astellas’ Xtandi has shown it is effective in men with prostate cancer that has spread but has not yet become hormone resistant, stepping up pressure on rival therapy Zytiga from Johnson

News

Bayer takes control of Loxo duo as Lilly closes takeover

Bayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the biotech was taken over by Eli Lilly in an

News

Keytruda combo set to become "standard of care" in kidney ca...

Analysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care in renal cell carcinoma (RCC) thanks to impressive trial results and a pr

News

NICE backs Takeda's Alunbrig in second-line lung cancer

NICE has published final draft guidance recommending regular NHS funding in England for Takeda’s Alunbrig (brigatinib), for ALK-positive advanced non-small cell lung cancer, in patients alr

News

Bayer/Orion showcase results from prostate cancer challenger

Bayer and development partner Orion have released detailed results from the trial that will form the backbone of its filing for their latest prostate cancer drug, as they aim to take on two

Two new cancer Priority Reviews for Roche

Trial could unlock new prostate cancer sales for Pfizer/Aste...

Bayer takes control of Loxo duo as Lilly closes takeover

Keytruda combo set to become "standard of care" in kidney ca...

NICE backs Takeda's Alunbrig in second-line lung cancer

Bayer/Orion showcase results from prostate cancer challenger

Datroway joins Trodelvy for frontline TNBC in the EU

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks